Nanoviricides Inc (NNVC)
1.10
-0.01
(-0.90%)
USD |
NYAM |
Apr 26, 14:51
Nanoviricides Cash from Financing (TTM): 0.00 for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.00 |
September 30, 2023 | -0.0238M |
June 30, 2023 | -0.0948M |
March 31, 2023 | -0.1275M |
December 31, 2022 | -0.1968M |
September 30, 2022 | -0.2343M |
June 30, 2022 | -0.2347M |
March 31, 2022 | -0.2725M |
December 31, 2021 | 5.849M |
September 30, 2021 | 4.835M |
June 30, 2021 | 15.26M |
March 31, 2021 | 24.65M |
December 31, 2020 | 26.39M |
September 30, 2020 | 28.42M |
June 30, 2020 | 17.83M |
March 31, 2020 | 8.512M |
December 31, 2019 | 3.067M |
September 30, 2019 | 2.108M |
June 30, 2019 | 2.35M |
March 31, 2019 | 2.35M |
December 31, 2018 | 0.00 |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | 6.743M |
March 31, 2015 | 11.74M |
December 31, 2014 | 31.18M |
September 30, 2014 | 31.14M |
June 30, 2014 | 34.34M |
March 31, 2014 | 29.24M |
December 31, 2013 | 14.09M |
September 30, 2013 | 16.39M |
June 30, 2013 | 6.511M |
March 31, 2013 | 8.796M |
December 31, 2012 | 6.825M |
September 30, 2012 | 6.967M |
June 30, 2012 | 9.328M |
March 31, 2012 | 9.465M |
December 31, 2011 | 7.175M |
September 30, 2011 | 7.036M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.2725M
Minimum
Mar 2022
28.42M
Maximum
Sep 2020
7.268M
Average
2.35M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
Gilead Sciences Inc | -5.125B |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |
Theriva Biologics Inc | 0.625M |